Actively Recruiting
Intermittent Fasting on the Blood Microbiome
Led by Erasmus Medical Center · Updated on 2025-02-26
48
Participants Needed
2
Research Sites
5 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators previously demonstrated that the gut microbiome can be remodeled by one month of intermittent fasting (OMIF) in healthy volunteers and animal models, with a notable alteration observed in its overall composition which could be linked to improvement in liver function. The blood microbiome, which mirrors the human ecosystem and includes all microbes mainly including bacteria, archaea, and viruses, is a new-identified human microbiome assessment tool that is assumed to be more stable and representative than the gut microbiome, with substantial potential for the diagnosis and prediction of liver cirrhosis and cancer. However, the effect of OMIF, which mimics lifestyle change typically advised in liver disease, on this blood microbiome remains elusive at best. The aim of this study is to explore whether OMIF remodels the composition and function of the blood microbiome in healthy volunteers, through a Randomized controlled cross-over trial, with secondary outcomes on the association of blood microbiome with the gut microbiome.
CONDITIONS
Official Title
Intermittent Fasting on the Blood Microbiome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-65 years
- Body mass index (BMI) between 18.5 and 25 kg/m2
- All genders are eligible
- Have not fasted (gone a day without food) for any days in the month before the study
- Willing to provide movement data through an app during the study
- Capable of giving written informed consent
You will not qualify if you...
- Regular use of medications like antibiotics, steroids, beta blockers, or adrenergic agents
- Regular use of prebiotics or probiotics
- Antibiotic use within the past month
- Daily consumption of more than 10 cigarettes or more than 6 cups of coffee
- Having chronic diseases such as type 2 diabetes, hypertension, fatty liver disease, cancer, or autoimmune disease
- Internal diseases affecting gastrointestinal tract, lung, heart, blood vessels, liver, or kidneys
- Eating disorders or unconventional eating habits
- Clinically significant abnormal blood test results
- Participation in another study
- Habit of regular fasting
- Pregnancy or breastfeeding (for women)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Northwest Minzu University
Lanzhou, Gansu, China, 730046
Actively Recruiting
2
Erasmus Medical Center - Department of Gastroenterology and Hepatology
Rotterdam, Netherlands, 3015 GD
Actively Recruiting
Research Team
M
Maikel P Peppelenbosch, MD, PhD
CONTACT
J
Junhong Su
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here